Article and Video CATEGORIES

Cancer Journey

Search By

 Dr. Zofia Piotrowska is with the Thoracic Oncology Program at Massachusetts General Hospital Cancer Center in Boston, Massachusetts.  More information on Dr. Piotrowska is available here: https://www.massgeneral.org/doctors/doctor.aspx?id=19711

2020 TTF EGFR QA Panel Increase in Leptomeningeal Disease & Connection with Mutation Pos. NSCLC
2020 TTF EGFR Session, Question and Answer Panel - The Increase in Leptomeningeal Disease & the Connection with Mutation Positive NSCLC
Author
Zofia (Zosia) Piotrowska, MD, GRACE Faculty
Image
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.  In this video from the EGFR Breakout Session, Drs. Jared Weiss and Zofia Piotrowska answer questions from attendees of the event.

For this video, the docs discuss the increase in leptomeningeal disease and the connection with mutation positive non small cell lung cancer.

 

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

 

Access to the full agenda can be found here: https://bit.ly/39131em

Full bios for attending faculty can be found here: https://bit.ly/2M0FVLH

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora